Is This the Right Time to Add Neogen Stock to Your Portfolio?

Neogen Corporation NEOG is advancing its product development efforts across food and animal safety, supported by increased investment in innovation. The company is building on its 3M Food Safety combination to expand manufacturing capacity and pursue new product opportunities. Animal Safety showed a sharper recovery in the fourth quarter of fiscal 2026 as supplier issues eased and product availability improved. Meanwhile, Neogen’s financial position remains pressured by high debt, while intense competition is also a risk.

Over the past year, this Zacks Rank #2 (Buy) stock has surged 107.7% against the 29.3% fall of the industry and the S&P 500’s 17.5% rise.

The renowned food and animal safety product provider has a market capitalization of $2.59 billion. Neogen surpassed earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 57%. 

Let’s delve deeper.

NEOG: Factors at Play

Product Launches: Neogen is expanding its food and animal safety pipeline with new products while shifting more resources toward differentiated technologies. Recent additions include Neogen MPNTray, the Listeria Right Now molecular detection assay, Igenity BCHF and MDA2 Quantitative Salmonella. Listeria Right Now earned AOAC Performance Tested Methods certification in fiscal 2026, supporting broader commercial use of the enrichment-free environmental monitoring test.

Management expects to raise fiscal 2027 R&D spending by about 50%, with investments spanning Petrifilm innovation, digital connectivity, licensed technologies and next-generation pathogen detection and sanitation platforms. Neogen expects the organic development cycle to take 18 to 24 months and plans multiple Petrifilm SKU launches as its in-house manufacturing capabilities expand.

Image Source: Zacks Investment Research

3M Integration Expands Opportunity: The 2022 combination with 3M’s Food Safety business continues to strengthen Neogen’s product breadth and manufacturing capabilities, with Petrifilm playing a key role. Neogen is bringing Petrifilm manufacturing in-house at its Lansing facility and expects to complete validation of the first SKU by the end of August 2026.

Sellable production and a multi-quarter manufacturing transition are expected to begin in November 2026. As the transfer moves forward, management expects duplicate manufacturing costs to decline, with benefits from the transition starting in the following fiscal year. The new platform is designed to accommodate further Petrifilm innovation, along with expansion into pharmaceuticals, nutraceuticals and consumer products. Neogen expects to launch at least two Petrifilm SKUs annually through the new process and has identified at least five candidates. These capabilities could extend the acquired platform beyond its original food and beverage testing base.

Animal Safety Supply Recovery: Neogen’s Animal Safety business entered fiscal 2027 with most of the third-party supplier issues that disrupted fiscal 2026 resolved. Fourth-quarter fiscal 2026 revenues fell 8.2% year over year, while core revenues rose 0.5% and sales increased more than 7% sequentially. The improvement followed an 8.7% core decline in the third quarter as product availability began to normalize.

Management also cited improving production animal markets, with higher meat prices supporting producer profitability and U.S. herd sizes showing signs of stabilization. Commercial resources are focused on priority products and accounts, while supplier qualification and quality processes are being tightened. Animal Safety is expected to grow more slowly than Food Safety in fiscal 2027, but the restored supply base and favorable end-market backdrop should support a more stable medium-term trajectory.

What Ails Neogen?

Weak Solvency: Neogen ended fiscal 2026 with $185.5 million in cash against about $800 million in debt. It repaid $20 million after year-end and plans to use roughly $140 million of expected net Genomics proceeds primarily for debt reduction, leaving deleveraging dependent on closing.

Tough Competitive Landscape: Neogen faces intense competition from companies ranging from small businesses to divisions of large multinational companies. Some of these organizations have substantially greater financial resources than the company. Historically, Neogen has faced intense competition resulting from the development of new technologies by competitors, which could affect the marketability and profitability of its products.

NEOG Stock’s Estimate Trend

In the past 30 days, the Zacks Consensus Estimate for Neogen’s earnings for fiscal 2027 has risen 3.3% to 31 cents.

The consensus mark for fiscal 2027 revenues is pegged at $883.2 million, which suggests a 1.5% rise from the prior year.

Other Key Picks

Some other top-ranked stocks in the broader medical space are Veracyte VCYT, Globus Medical GMED and Teleflex TFX.

Veracyte has an earnings yield of 4.5% against the industry’s negative 1.3% yield. Shares of the company have risen 42.3% against the industry’s 5% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%. 

VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Globus Medical, carrying a Zacks Rank #2, has an earnings yield of 6% against the industry’s negative 1.3% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 27.5% against the industry’s 5% drop over the past year.

Teleflex, carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.9% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have gained 4.2% against the industry’s 5% decline over the past year.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research